SAFETY DATA SHEET

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name                                      Pfizer-BioNTech COVID-19 Vaccine
Product Code(s)                                   PF00092
Synonyms                                          PF-07302048 containing PF-07305885 (BNT162b2); CorVAC Containing PF-07305885 (BNT162b2); CoVVAC Containing PF-07305885 (BNT162b2); COVID Vaccine Containing PF-07305885 (BNT162b2); COVID-19 Vaccine Containing PF-07305885 (BNT162b2)
Trade Name:                                      Not applicable
Compound Number                                  PF-07302048
Item Code                                        H000022941: H000023057
Chemical Family:                                 Lipid Nanoparticles containing PF-07305885 (BNT162b2) and Lipids

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use                                  Pharmaceutical product

1.3. Details of the supplier of the safety data sheet

Pfizer Inc                                        Pfizer Ltd
235 East 42nd Street                              Ramsgate Road
New York, New York 10017                           Sandwich, Kent
1-800-879-3477                                     CT13 9NU
                                                United Kingdom
                                                +00 44 (0)1304 616161

1.4. Emergency telephone number

Emergency Telephone                              Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887
E-mail address                                   pfizer-MSDS@pfizer.com

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

Not classified as hazardous

2.2. Label elements

Signal word                                      Not classified
Hazard statements                                Not classified in accordance with international standards for workplace safety.

2.3. Other hazards

Other hazards                                    An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).
Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

NonHazardous

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>EC No</th>
<th>CAS No</th>
<th>Weight-%</th>
<th>Classification according to Regulation (EC) No. 1272/2008 [CLP]</th>
<th>REACH Registration Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water</td>
<td>231-791-2</td>
<td>7732-18-5</td>
<td>*</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Sucrose</td>
<td>200-334-9</td>
<td>57-50-1</td>
<td>&lt; 10</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>SODIUM CHLORIDE</td>
<td>231-598-3</td>
<td>7647-14-5</td>
<td>&lt; 10</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>ALC-0315</td>
<td>Not Listed</td>
<td>NOT ASSIGNED</td>
<td>&lt; 2</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Potassium phosphate</td>
<td>231-913-4</td>
<td>7778-77-0</td>
<td>&lt; 1</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>POTASSIUM CHLORIDE</td>
<td>231-211-8</td>
<td>7447-40-7</td>
<td>&lt; 1</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>PF-07305885</td>
<td>Not Listed</td>
<td>NOT ASSIGNED</td>
<td>&lt; 1</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>PF-07302048</td>
<td>Not Listed</td>
<td>NOT ASSIGNED</td>
<td>&lt; 1</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>PEGA / ALC-0159</td>
<td>Not Listed</td>
<td>NOT ASSIGNED</td>
<td>&lt; 1</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Disodium phosphate dihydrate</td>
<td>Not Listed</td>
<td>10028-24-7</td>
<td>&lt; 1</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Cholesterol</td>
<td>200-353-2</td>
<td>57-88-5</td>
<td>&lt; 1</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>1,2-Distearoyl-sn-glycero-3-phosphocholine</td>
<td>212-440-2</td>
<td>816-94-4</td>
<td>&lt; 1</td>
<td>Not Listed</td>
<td></td>
</tr>
</tbody>
</table>

Full text of H- and EUH-phrases: see section 16

Additional information

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation Remove to fresh air. Seek immediate medical attention/advice.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.

Skin contact Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects

No data available
Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media: Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical: Fine particles (such as mists) may fuel fires/explosions.

Hazardous combustion products: Formation of toxic gases is possible during heating or fire.

5.3. Advice for firefighters

Special protective equipment for fire-fighters: Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders: Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment: Prevent further leakage or spillage if safe to do so.

Methods for cleaning up: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Prevention of secondary hazards: Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections: See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling: Restrict access to work area. No open handling permitted. Minimize generating airborne mists and vapors. If solvent based liquid, ground and bond all bulk transfer equipment. Use appropriate engineering controls to maintain exposures below the B-OEB taking all applicable routes of exposure into consideration. A change area to facilitate ‘good laboratory/manufacturing’ decontamination practices is recommended. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere.
should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

**General hygiene considerations**  Handle in accordance with good industrial hygiene and safety practice.

**7.2. Conditions for safe storage, including any incompatibilities**

**Storage Conditions**  Store at < -70 °C in properly labeled containers. Keep away from heat, sparks, and flames.

**7.3. Specific end use(s)**

**Specific use(s)**  Vaccine.

## Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

**8.1. Control parameters**

**Exposure Limits**

Refer to available public information for specific member state Occupational Exposure Limits.

<table>
<thead>
<tr>
<th>Substance</th>
<th>Exposure Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sucrose</strong></td>
<td></td>
</tr>
<tr>
<td>ACGIH TLV</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>10.0 mg/m³</td>
</tr>
<tr>
<td>Estonia</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>France</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Ireland</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Latvia</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Spain</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>OSHA PEL</td>
<td>15 mg/m³</td>
</tr>
<tr>
<td>TWA</td>
<td>30 mg/m³</td>
</tr>
<tr>
<td>STEL</td>
<td>20 mg/m³</td>
</tr>
<tr>
<td>United Kingdom</td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM CHLORIDE</strong></td>
<td></td>
</tr>
<tr>
<td>Latvia</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Russia</td>
<td>MAC: 5 mg/m³</td>
</tr>
<tr>
<td><strong>Potassium phosphate</strong></td>
<td></td>
</tr>
<tr>
<td>Russia</td>
<td>MAC: 10 mg/m³</td>
</tr>
<tr>
<td><strong>POTASSIUM CHLORIDE</strong></td>
<td></td>
</tr>
<tr>
<td>Bulgaria</td>
<td>5.0 mg/m³</td>
</tr>
<tr>
<td>Latvia</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Russia</td>
<td>MAC: 5 mg/m³</td>
</tr>
</tbody>
</table>

**Pfizer OEB Statement:**  The Biotherapeutic Occupational Exposure Band (B-OEB) is an acceptable daily intake (ADI) range, based on available hazard data with appropriate safety factors applied. Engineering control measures should be utilized to bring exposures into the relevant B-OEB; supplementary administrative controls and personal protective equipment are to be used to achieve exposure control to the bottom of the band.

<table>
<thead>
<tr>
<th>Substance</th>
<th>OEB Band (µg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SODIUM CHLORIDE</strong></td>
<td></td>
</tr>
<tr>
<td>Pfizer Occupational Exposure Band (OEB):</td>
<td>OEB 1 (control exposure to the range of 1000µg/m³ to 3000µg/m³)</td>
</tr>
<tr>
<td><strong>POTASSIUM CHLORIDE</strong></td>
<td></td>
</tr>
<tr>
<td>Pfizer Occupational Exposure Band (OEB):</td>
<td>OEB 1 (control exposure to the range of 1000µg/m³ to 3000µg/m³)</td>
</tr>
<tr>
<td><strong>PF-07305885</strong></td>
<td></td>
</tr>
<tr>
<td>Pfizer Occupational Exposure Band (OEB):</td>
<td>B-OEB Default (control exposure to the range of 10 µg/day to &lt;100 µg/day)</td>
</tr>
<tr>
<td><strong>PF-07302048</strong></td>
<td></td>
</tr>
<tr>
<td>Pfizer Occupational Exposure Band (OEB):</td>
<td>B-OEB 5 (control exposure to &lt;10 µg/day)</td>
</tr>
</tbody>
</table>
Band (OEB):

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, biosafety cabinet, or other engineering controls to maintain airborne levels within the B-OEB range. It is recommended that all large scale operations should be fully enclosed. Air recirculation is not recommended.

Environmental exposure controls

No information available.

Personal protective equipment

Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Eye/face protection

Wear safety glasses as minimum protection (goggles recommended). (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection

Wear impervious disposable gloves (e.g. Nitrile, etc.) as minimum protection (double recommended). (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection

Wear impervious disposable protective clothing when handling this compound. Full body protection is recommended (scale dependent). Wear impervious protective clothing when handling this compound. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection

Under normal conditions of use, if the applicable Biotherapeutic Occupational Exposure Band (B-OEB) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the B-OEB (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.).

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical state</td>
<td>Liquid</td>
</tr>
<tr>
<td>Color</td>
<td>milky white</td>
</tr>
<tr>
<td>Molecular formula (MF):</td>
<td>Mixture</td>
</tr>
<tr>
<td>Molecular weight</td>
<td>Mixture</td>
</tr>
<tr>
<td>Odor</td>
<td>No data available.</td>
</tr>
<tr>
<td>Odor threshold</td>
<td>No data available.</td>
</tr>
<tr>
<td>pH</td>
<td>7.4</td>
</tr>
<tr>
<td>Melting point / freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Boiling point / boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>No data available.</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available.</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>No data available.</td>
</tr>
<tr>
<td>Flammability Limit in Air</td>
<td></td>
</tr>
<tr>
<td>Upper flammability limit:</td>
<td>No data available.</td>
</tr>
<tr>
<td>Lower flammability limit:</td>
<td>No data available.</td>
</tr>
</tbody>
</table>
**SAFETY DATA SHEET**

**Product Name**  Pfizer-BioNTech COVID-19 Vaccine

**Revision date**  16-Nov-2020  **Version**  1.02

---

**9.2. Other information**

- **Vapor pressure**: No data available
- **Vapor density**: No data available
- **Relative density**: No data available
- **Water solubility**: No data available
- **Solubility(ies)**: No data available
- **Autoignition temperature**: No data available
- **Decomposition temperature**: No data available
- **Kinematic viscosity**: No data available
- **Dynamic viscosity**: No data available
- **Explosive properties**: No data available
- **Oxidizing properties**: No data available
- **Liquid Density**: No data available
- **Bulk density**: No data available

---

**Section 10: STABILITY AND REACTIVITY**

10.1. Reactivity

Reactivity: No data available.

10.2. Chemical stability

Stability: Stable under normal conditions.

Explosion data

- Sensitivity to Mechanical Impact: No data available.
- Sensitivity to Static Discharge: No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions: No information available.

10.4. Conditions to avoid

Conditions to avoid: Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge.

10.5. Incompatible materials

Incompatible materials: As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products: No data available.

---

**Section 11: TOXICOLOGICAL INFORMATION**

11.1. Information on toxicological effects

**General Information:**

Toxicological properties have not been thoroughly investigated. The following information is available for the individual ingredients.

**Known Clinical Effects:**

Based on clinical trials in humans, possible adverse effects following intravenous exposure to this compound may include: muscle pain, abnormal redness of skin (erythema), fever, and sleep disturbances.

**Acute Toxicity: (Species, Route, End Point, Dose)**

- **Sucrose**
  - Rat Oral  LD 50  29,700 mg/kg

- **SODIUM CHLORIDE**
  - Rat Sub-tenon injection (eye) LC50/1hr  > 42 g/m³
  - Rat Oral  LD 50  3 g/kg

---

PF00092
Mouse  Oral  LD 50  4 g/kg  
Rabbit  Dermal  LD 50  > 10 g/kg  

**POTASSIUM CHLORIDE**
Rat  Oral  LD50  2600 mg/kg  

**Potassium phosphate**
Rat  Oral  LD50  3200 mg/kg  
Rabbit  Dermal  LC50  > 4640 mg/kg  

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Oral LD50</th>
<th>Dermal LD50</th>
<th>Inhalation LC50</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water</td>
<td>&gt; 90 mL/kg (Rat)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sucrose</td>
<td>= 29700 mg/kg (Rat)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SODIUM CHLORIDE</td>
<td>= 3 g/kg (Rat)</td>
<td>-</td>
<td>&gt; 42 g/m³ (Rat) 1 h</td>
</tr>
<tr>
<td>Potassium phosphate</td>
<td>= 3200 mg/kg (Rat)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>POTASSIUM CHLORIDE</td>
<td>= 2600 mg/kg (Rat)</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**Irritation / Sensitization: (Study Type, Species, Severity)**

**SODIUM CHLORIDE**
Skin Irritation  Rabbit  Mild  
Eye Irritation  Rabbit  Mild  

**POTASSIUM CHLORIDE**
Eye Irritation  Rabbit  Mild  

**Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)**

**PF-07302048**
4 Week(s)  Rat  Intramuscular  * 10 µg  LOAEL  Skin, Blood forming organs, Blood, Skeletal muscle, Lymphoid tissue, Spleen  
**Repeated Dose Toxicity Comments:**  PF-07302048:  * Doses were administered once a week.  

**Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

**Potassium phosphate**
Reproductive & Fertility  Rat  No route specified  282 mg/kg/day  NOAEL  No evidence of impaired fertility or harm to the fetus  
Reproductive & Fertility  Mouse  No route specified  320 mg/kg/day  NOAEL  No evidence of impaired fertility or harm to the fetus  

**Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

**Potassium phosphate**
Bacterial Mutagenicity (Ames)  Salmonella  Negative  

Carcinogenicity  
Cholesterol  

IARC  
Group 3 (Not Classifiable)  

---

**Section 12: ECOLOGICAL INFORMATION**

**Environmental Overview:**  Environmental properties have not been investigated. Releases to the environment should be avoided.  

**12.1. Toxicity**

**Aquatic Toxicity: (Species, Method, End Point, Duration, Result)**

**POTASSIUM CHLORIDE**
Gambusia affinis (Mosquitofish)  LC50  96 hours  920 mg/l
Lepomis macrochirus (Bluegill Sunfish) LC50 96 hours 2010 mg/L
Daphnia Magna (Water Flea) EC50 48 hours 825 mg/l
Scenedesmus subspicatus (Green Alga) EC50 72 Hours 2500 mg/L

12.2. Persistence and degradability
Persistence and degradability
No information available.

12.3. Bioaccumulative potential
Bioaccumulation
No information available.

12.4. Mobility in soil
Mobility in soil
No information available.

12.5. Results of PBT and vPvB assessment
PBT and vPvB assessment
No information available.

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>PBT and vPvB assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM CHLORIDE</td>
<td>The substance is not PBT / vPvB PBT assessment does not apply</td>
</tr>
<tr>
<td>Potassium phosphate</td>
<td>The substance is not PBT / vPvB PBT assessment does not apply</td>
</tr>
<tr>
<td>POTASSIUM CHLORIDE</td>
<td>The substance is not PBT / vPvB PBT assessment does not apply</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>The substance is not PBT / vPvB</td>
</tr>
</tbody>
</table>

12.6. Other adverse effects
Other adverse effects
No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods
Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.
Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water
- CERCLA/SARA Section 313 de minimus %: Not Listed
- California Proposition 65: Not Listed
- TSCA: Present
- EINECS: 231-791-2
- AICS: Present

Sucrose
- CERCLA/SARA Section 313 de minimus %: Not Listed
- California Proposition 65: Not Listed
- TSCA: Present
- EINECS: 200-334-9
- AICS: Present

SODIUM CHLORIDE
- CERCLA/SARA Section 313 de minimus %: Not Listed
- California Proposition 65: Not Listed
- TSCA: Present
- EINECS: 231-598-3
- AICS: Present

ALC-0315
- CERCLA/SARA Section 313 de minimus %: Not Listed
- California Proposition 65: Not Listed
- EINECS: Not Listed

Potassium phosphate
- CERCLA/SARA Section 313 de minimus %: Not Listed
- California Proposition 65: Not Listed
- TSCA: Present
- EINECS: 231-913-4
- AICS: Present

POTASSIUM CHLORIDE
- CERCLA/SARA Section 313 de minimus %: Not Listed
- California Proposition 65: Not Listed
- TSCA: Present
- EINECS: 231-211-8
- AICS: Present

Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)

PF-07305885
- CERCLA/SARA Section 313 de minimus %: Not Listed
- California Proposition 65: Not Listed
- EINECS: Not Listed

PF-07302048
- CERCLA/SARA Section 313 de minimus %: Not Listed
- California Proposition 65: Not Listed
- EINECS: Not Listed

PEGA / ALC-0159
- CERCLA/SARA Section 313 de minimus %: Not Listed
- California Proposition 65: Not Listed
- EINECS: Not Listed

Disodium phosphate dihydrate
- CERCLA/SARA Section 313 de minimus %: Not Listed
- California Proposition 65: Not Listed
- EINECS: Not Listed
- AICS: Present

Standard for Uniform Scheduling of Medicines and Poisons: Schedule 5
15.2. Chemical safety assessment

Chemical Safety Report

No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Revision date 16-Nov-2020

Prepared By Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.